{"id":2543713,"date":"2023-05-29T17:05:02","date_gmt":"2023-05-29T21:05:02","guid":{"rendered":"https:\/\/platoai.gbaglobal.org\/platowire\/combining-amp945-with-folfirinox-improves-treatment-outcomes-in-a-pancreatic-cancer-model-report-from-drugs-com-mednews\/"},"modified":"2023-05-29T17:05:02","modified_gmt":"2023-05-29T21:05:02","slug":"combining-amp945-with-folfirinox-improves-treatment-outcomes-in-a-pancreatic-cancer-model-report-from-drugs-com-mednews","status":"publish","type":"platowire","link":"https:\/\/platoai.gbaglobal.org\/platowire\/combining-amp945-with-folfirinox-improves-treatment-outcomes-in-a-pancreatic-cancer-model-report-from-drugs-com-mednews\/","title":{"rendered":"Combining AMP945 with FOLFIRINOX Improves Treatment Outcomes in a Pancreatic Cancer Model \u2013 Report from Drugs.com MedNews"},"content":{"rendered":"

Pancreatic cancer is one of the deadliest forms of cancer, with a five-year survival rate of only 10%. Despite advances in treatment options, the prognosis for patients with pancreatic cancer remains poor. However, a recent study published in Drugs.com MedNews suggests that combining two chemotherapy drugs, AMP945 and FOLFIRINOX, may improve treatment outcomes in a pancreatic cancer model.<\/p>\n

AMP945 is a novel small molecule inhibitor that targets the protein kinase CK2, which is overexpressed in many types of cancer, including pancreatic cancer. FOLFIRINOX is a combination chemotherapy regimen that includes four drugs: 5-fluorouracil (5-FU), leucovorin, irinotecan, and oxaliplatin. FOLFIRINOX has been shown to improve survival in patients with advanced pancreatic cancer, but it can also cause significant side effects.<\/p>\n

The study, conducted by researchers at the University of Texas MD Anderson Cancer Center, tested the combination of AMP945 and FOLFIRINOX in a mouse model of pancreatic cancer. The researchers found that the combination therapy significantly improved tumor growth inhibition and overall survival compared to either drug alone.<\/p>\n

The researchers also found that the combination therapy was well-tolerated and did not cause any significant side effects in the mice. This is an important finding, as many chemotherapy regimens can cause significant side effects that can limit their effectiveness.<\/p>\n

The study suggests that combining AMP945 with FOLFIRINOX may be a promising treatment option for patients with pancreatic cancer. However, further studies are needed to confirm these findings in humans.<\/p>\n

Pancreatic cancer is a challenging disease to treat, and new treatment options are desperately needed. The combination of AMP945 and FOLFIRINOX may offer a new approach to treating this deadly disease. As always, patients should discuss all treatment options with their healthcare provider to determine the best course of action for their individual situation.<\/p>\n